Novavax Inc (NVAX)
Novavax, Inc. is a biotechnology company focused on discovering, developing, and commercializing vaccines for serious infectious diseases in the United States, Europe, and other international markets. The company markets Nuvaxovid, its COVID-19 vaccine, and the R21 Matrix-M adjuvant malaria vaccine. Novavax also has collaboration and license agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited related to the development, manufacture, and commercialization of its COVID-19 vaccine. Incorporated in 1987, Novavax is headquartered in Gaithersburg, Maryland. Its common stock is listed on the NASDAQ exchange under the symbol NVAX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NVAX
|
$7.17
|
-10.9% Downside
|
Fair
|
$14.11
|
75.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-15.1x
|
-9.1x
|
2.2x
|
1.296 B
|
828.5 M
|
18.5%
|
86.0%
|
-4.8
|
—
|
110.2%
|
